• Successful retail launch of Nasodine® Nasal Spray in Singapore
• Strong growth in US online sales of Nasodine
• Expanded international distribution with Fiji and South Pacific licensing deal
• Preparing for Nasodine launch in Philippines by mid-2026

Firebrick Pharma has reported a strong quarter, with the retail launch of Nasodine® Nasal Spray in Singapore, where it is now available in 125 Guardian pharmacies. The company also saw significant growth in US online sales, with a 44% increase in orders from the previous quarter and a 135% increase from Q1. This was driven by growing adoption of Nasodine in the US, as well as marketing initiatives. Firebrick also expanded its international distribution, signing a licensing and distribution agreement with Makans Limited for Fiji and the South Pacific. The company received its first order from Makans during the quarter. In the Philippines, Nasodine was successfully manufactured, and after stability testing, Firebrick's partner SV More will file for regulatory approval, with a potential launch by mid-2026. Firebrick also successfully defended its core patent for Nasodine in Singapore, removing a competitor product from the market. The company's cash position improved during the quarter, with $1.38 million in cash and cash equivalents at the end of March, up from $0.91 million in the previous quarter. Net cash outflow from operations also decreased by 30% compared to the previous quarter.

Firebrick is focused on driving continued growth in Singapore, the US, and its new markets, while preparing for the Philippines launch. The company will continue to look for ways to grow sales in the US while keeping marketing costs low and the business cash flow positive or neutral.